Business Wire

NY-JETBLUE

29.4.2021 19:07:13 CEST | Business Wire | Press release

Share
JetBlue Takes Delivery of First Airbus A321LR Aircraft Enabling Airline to Launch First-Ever Transatlantic Service

JetBlue (NASDAQ: JBLU) today announced it has taken delivery of the airline’s first Airbus A321 Long Range (LR) aircraft, with tail N4022J arriving at JetBlue’s home at John F. Kennedy International Airport (JFK) Terminal 5 this afternoon. This A321LR was assembled at the Airbus production facility in Hamburg, Germany and will enable JetBlue to launch its first-ever transatlantic service between the U.S. and London this summer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005942/en/

“The delivery of our new A321LR sets the stage for a new era at JetBlue in which we now have an aircraft allowing us to stretch our wings and become a true global carrier offering flights beyond the Americas for the first time ever,” said Robin Hayes, chief executive officer, JetBlue. “The A321LR platform – offering the range of a wide-body but with the economics of a single-aisle aircraft – is the right size for us and will allow us to effectively compete with our award-winning service and low fares on flights between the U.S. and London. We congratulate Airbus on bringing to life the most exciting and innovative narrow bodied aircraft cabin in the world and JetBlue is honored to be the launch customer for Airspace on the A320 family.”

The A321LR allows JetBlue to tap into new long-haul markets, like London, that were not previously accessible with the airline’s existing fleet. The LR’s range of up to 4,000 nautical miles is made possible by three additional center fuel tanks and the aircraft delivers 30 percent fuel savings and nearly 50 percent reduction in noise footprint compared to previous generations of aircraft. JetBlue converted 13 aircraft in its existing A321 order book to the LR version in April 2019 with the ability to convert more. Additionally, JetBlue has converted another 13 aircraft in its existing order book to the Extra-Long Range – or XLR – version of the A321.

JetBlue is also the global launch partner for the new Airspace by Airbus cabin, bringing long-haul style to the A321 for the first time ever. Airspace brings a series of enhancements, many customized for JetBlue, including:

  • Stunning backlit ceiling panels through the entire cabin, which glow with a unique-to-JetBlue pattern.
  • Custom LED mood lighting that changes throughout different phases of flight to reduce jetlag technologies.
  • The largest overhead bins on a single-aisle aircraft.
  • New ergonomic sidewalls creating extra personal space at shoulder level.
  • A re-designed welcome area at the front boarding door.
  • Refreshed onboard restrooms with antimicrobial surfaces.

The modern elements of Airspace, combined with the customizations by JetBlue, offer customers a boutique-style setting for the airline’s highly anticipated transatlantic service.

“We are honored that JetBlue is our first launch operator for the new Airspace cabin on Airbus Single-Aisle aircraft. We are also confident that the airline’s customers and crew alike will appreciate the outstanding comfort and in-flight transatlantic experience on board these aircraft,” said Christian Scherer, Airbus Chief Commercial Officer.

JetBlue’s A321LR is powered by two Pratt & Whitney GTF engines. The GTF engine, with its revolutionary geared fan technology, is transforming aviation by delivering game-changing economic and environmental performance. The Pratt & Whitney GTF engine also incorporates advances in aerodynamics, lightweight materials and other major technology improvements.

“Today we celebrate another exciting and historical milestone between Pratt & Whitney and JetBlue,” said Carroll Lane, president of Commercial Engines at Pratt & Whitney. “The GTF-powered Airbus A321LR aircraft will allow JetBlue to fly farther, opening new routes for their customers, while delivering the economic and environmental benefits of our game-changing engine. We look forward to continuing to power their fleet for decades to come.”

Known in the U.S. for having the most legroom in coach (a), live television and on-demand entertainment on every seatback, free Fly-Fi broadband internet (b), complimentary snacks and soft drinks, and great customer service, JetBlue’s entrance into the transatlantic market will introduce a new era of customer-focused, low-fare travel for leisure and business travelers.

The airline’s Mint® premium experience – which first disrupted transcontinental travel in the U.S. and has been completely reimagined for transatlantic flying – promises to offer customers a fresh choice when flying between the U.S. and the U.K. JetBlue Mint features 24 fully lie-flat private suites with a sliding door, a custom-designed seat cushion by Tuft & Needle, and countless design touches that help every customer feel at home in the air. As part of the refresh, JetBlue will also introduce its latest innovation, the stunning Mint Studio™, which will offer the most space in a premium experience from any U.S. airline (c).

JetBlue’s industry-leading core experience has also been reinvented for crossing the pond and will offer a new level of service to customers who want a great experience at a low fare. All of the comforts JetBlue customers have come to expect will be enhanced by the recently announced partnership with Dig to bring its signature build-your-own dining concept to tray tables at 35,000 feet – JetBlue’s first complimentary meal in core. With just 114 core seats, core customers will enjoy a boutique-style experience no matter where they sit.

Customers in both core and Mint will be able to stay connected throughout the flight with the airline’s popular unlimited, free high-speed Wi-Fi. In addition, customers will have access to a curated selection of live TV channels focused on news and sports, and an extensive library of seatback entertainment – allowing customers to have a multiple screen experience onboard, just like they do at home.

Additional details about specific London routes, schedules and out-for-sale dates will be announced soon.

For the latest JetBlue London news visit: https://www.jetblue.com/flying-with-us/london

For more on the JetBlue’s A321LR aircraft visit: https://www.jetblue.com/flying-with-us/our-planes/A321-long-range

About JetBlue Airways

JetBlue is New York's Hometown Airline®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando and San Juan. JetBlue carries customers across the U.S., Caribbean and Latin America. For more information, visit jetblue.com .

(a)

 

JetBlue offers the most legroom in coach based on average fleet-wide seat pitch for U.S.

airlines.

 

 

(b)

 

Fly-Fi® and live television are available on all JetBlue-operated flights. Availability and coverage area may vary by aircraft. Details on inflight Wi-Fi and entertainment:

https://www.jetblue.com/flying-with-us/wifi .

 

 

(c)

Based on personal square footage per passenger seat.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye